Formaldehyde-activated pixantrone is a monofunctional DNA alkylator that binds selectively to CpG and CpA doublets

Molecular Pharmacology

Volumn 74, Issue 1, 2008, Pages 184-194

  Evison, Benny J ^a   Chiu, Francis ^b   Pezzoni, Gabriella ^c   Phillips, Don R ^a   Cutts, Suzanne M ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c Cell Therapeutics Europe   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAQUINONE DERIVATIVE; BBR 2378; CARBENE; CYTOSINE; DINUCLEOTIDE; DNA; DOXORUBICIN; FORMALDEHYDE; GUANINE; INOSINE; MITOXANTRONE; OLIGONUCLEOTIDE; PIXANTRONE; POLYNUCLEOTIDE;

ARTICLE; COMPLEX FORMATION; COVALENT BOND; CROSS LINKING; DNA ADDUCT; DNA ALKYLATION; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; GENETIC TRANSCRIPTION; MASS SPECTROMETRY; METHYLATION; PRIORITY JOURNAL;

ADENINE NUCLEOTIDES; ALKYLATING AGENTS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CPG ISLANDS; DNA ADDUCTS; DNA METHYLATION; FORMALDEHYDE; ISOQUINOLINES; MOLECULAR STRUCTURE;

EID: 45749147791     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.045625     Document Type: Article

References (40)

1. Beljanski V, Marzilli LG, and Doetsch PW (2004) DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs. Mol Pharmacol 65:1496-1506.
2. Capranico G and Binaschi M (1998) DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim Biophys Acta 1400:185-194.
3. Cavalletti E, Crippa L, Mainardi P, Oggioni N, Cavagnoli R, Bellini O, and Sala F (2007) Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs 25:187-195.
4. Cutts SM, Rephaeli A, Nudelman A, Hmelnitsky I, and Phillips DR (2001) Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res 61:8194-8202.
5. Cutts SM, Swift LP, Pillay V, Forrest RA, Nudelman A, Rephaeli A, and Phillips DR (2007) Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate. Mol Cancer Ther 6:1450-1459.
6. David-Cordonnier MH, Laine W, Lansiaux A, Kouach M, Briand G, Pierre A, Hickman JA, and Bailly C (2002) Alkylation of guanine in DNA by S23906-1, a novel potent antitumor compound derived from the plant alkaloid acronycine. Biochemistry 41:9911-9920.
7. De Isabella P, Palumbo M, Sissi C, Capranico G, Carenini N, Menta E, Oliva A, Spinelli S, Krapcho AP, Giuliani FC, et al. (1995) Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol 48:30-38.
8. DeVita VT, Hellman S and Rosenberg SA (2001) Principles and Practice of Oncology, 6th ed, Lippincott-Raven, Philadelphia PA.
9. DuVernay VH Jr., Pachter JA, and Crooke ST (1979) Deoxyribonucleic acid binding studies on several new anthracycline antitumor antibiotics. Sequence preference and structure-activity relationships of marcellomycin and its analogues as compared to adriamycin. Biochemistry 18:4024-4030.
10. Ebeler SE, Clifford AJ, and Shibamoto T (1997) Quantitative analysis by gas chromatography of volatile carbonyl compounds in expired air from mice and human. J Chromatogr B Biomed Sci Appl 702:211-215.
11. Engert A, Herbrecht R, Santoro A, Zinzani PL, and Gorbatchevsky I (2006) EXTEND PIX301: a phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 7:152-154.
12. Evison BJ, Mansour OC, Menta E, Phillips DR, and Cutts SM (2007) Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. Nucleic Acids Res 35:3581-3589.
13. Faulds D, Balfour JA, Chrisp P, and Langtry HD (1991) Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 41:400-449.
14. Fox KR, Waring MJ, Brown JR, and Neidle S (1986) DNA sequence preferences for the anti-cancer drug mitoxanthrone and related anthraquinones revealed by DNase I footprinting. FEBS Lett 202:289-294.
15. Hemminki K and Ludlum DB (1984) Covalent modification of DNA by antineoplastic agents. J Natl Cancer Inst 73:1021-1028.
16. Hurley LH (1989) DNA and associated targets for drug design. J Med Chem 32:2027-2033.
17. Hurley LH (2002) DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2:188-200.
18. Kato S, Burke PJ, Koch TH, and Bierbaum VM (2001) Formaldehyde in human cancer cells: detection by preconcentration-chemical ionization mass spectrometry. Anal Chem 73:2992-2997.
19. Laird PW (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3:253-266.
20. Lawley PD (1995) Alkylation of DNA and its aftermath. Bioessays 17:561-568.
21. Li VS, Reed M, Zheng Y, Kohn H, and TangM(2000) C5 cytosine methylation at CpG sites enhances sequence selectivity of mitomycin C-DNA bonding. Biochemistry 39:2612-2618.
22. Lown JW, Morgan AR, Yen SF, Wang YH, and Wilson WD (1985) Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry 24:4028-4035.
23. Momparler RL and Bovenzi V (2000) DNA methylation and cancer. J Cell Physiol 183:145-154.
24. Murray V (1999) A survey of the sequence-specific interaction of damaging agents with DNA: emphasis on antitumor agents. Prog Nucleic Acid Res Mol Biol 63:367-415.
25. Palumbo M, Gatto B, Moro S, Sissi C, and Zagotto G (2002) Sequence-specific interactions of drugs interfering with the topoisomerase-DNA cleavage complex. Biochim Biophys Acta 1587:145-154.
26. Panousis C and Phillips DR (1994) DNA sequence specificity of mitoxantrone. Nucleic Acids Res 22:1342-1345.
27. Parker BS, Buley T, Evison BJ, Cutts SM, Neumann GM, Iskander MN, and Phillips DR (2004a) A molecular understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences. J Biol Chem 279:18814-18823.
28. Parker BS, Cutts SM, Cullinane C, and Phillips DR (2000) Formaldehyde activation of mitoxantrone yields CpG and CpA specific DNA adducts. Nucleic Acids Res 28:982-990.
29. Parker BS, Cutts SM, and Phillips DR (2001) Cytosine methylation enhances mitoxantrone-DNA adduct formation at CpG dinucleotides. J Biol Chem 276:15953-15960.
30. Parker BS, Rephaeli A, Nudelman A, Phillips DR, and Cutts SM (2004b) Formation of mitoxantrone adducts in human tumor cells: potentiation by AN-9 and DNA methylation. Oncol Res 14:279-290.
31. Phillips DR, Cutts SM, Cullinane CM, and Crothers DM (2001) High-resolution transcription assay for probing drug-DNA interactions at individual drug sites. Methods Enzymol 340:466-485.
32. Rajski SR and Williams RM (1998) DNA Cross-Linking Agents as Antitumor Drugs. Chem Rev 98:2723-2796.
33. Skladanowski A and Konopa J (1994a) Interstrand DNA crosslinking induced by anthracyclines in tumour cells. Biochem Pharmacol 47:2269-2278.
34. Skladanowski A and Konopa J (1994b) Relevance of interstrand DNA crosslinking induced by anthracyclines for their biological activity. Biochem Pharmacol 47:2279-2287.
35. Swift LP, Rephaeli A, Nudelman A, Phillips DR, and Cutts SM (2006) Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 66:4863-4871.
36. Taatjes DJ, Gaudiano G, Resing K, and Koch TH (1997) Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J Med Chem 40:1276-1286.
37. Trist H and Phillips DR (1989) In vitro transcription analysis of the role of flanking sequence on the DNA sequence specificity of adriamycin. Nucleic Acids Res 17:3673-3688.
38. van Rosmalen A, Cullinane C, Cutts SM, and Phillips DR (1995) Stability of adriamycin-induced DNA adducts and interstrand crosslinks. Nucleic Acids Res 23:42-50.
39. Wang AH, Gao YG, Liaw YC, and Li YK (1991) Formaldehyde cross-links daunorubicin and DNA efficiently: HPLC and X-ray diffraction studies. Biochemistry 30:3812-3815.
40. Zeman SM, Phillips DR, and Crothers DM (1998) Characterization of covalent adriamycin-DNA adducts. Proc Natl Acad Sci U S A 95:11561-11565.